Investigational Drug Information for Obicetrapib
✉ Email this page to a colleague
What is the drug development status for Obicetrapib?
Obicetrapib is an investigational drug.
There have been 11 clinical trials for Obicetrapib.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Atherosclerosis. The leading clinical trial sponsors are NewAmsterdam Pharma, Veranex, and Pharma Medica Research, Inc.
There are three US patents protecting this investigational drug and eighty-nine international patents.
Summary for Obicetrapib
| US Patents | 3 |
| International Patents | 89 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2022-02-01) |
| Vendors | 21 |
Recent Clinical Trials for Obicetrapib
| Title | Sponsor | Phase |
|---|---|---|
| Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe | NewAmsterdam Pharma | Phase 1 |
| PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | Veranex | Phase 1 |
| PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | NewAmsterdam Pharma | Phase 1 |
Clinical Trial Summary for Obicetrapib
Top disease conditions for Obicetrapib
Top clinical trial sponsors for Obicetrapib
US Patents for Obicetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Obicetrapib | ⤷ Sign Up | Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives | DEZIMA PHARMA B.V. (Naarden, NL) | ⤷ Sign Up |
| Obicetrapib | ⤷ Sign Up | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | DEZIMA PHARMA B.V. (NL) | ⤷ Sign Up |
| Obicetrapib | ⤷ Sign Up | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | DEZIMA PHARMA BV (NL) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Obicetrapib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Obicetrapib | Argentina | AR101509 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Australia | AU2015302407 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Brazil | BR112017002873 | 2034-08-12 | ⤷ Sign Up |
| Obicetrapib | Canada | CA2958040 | 2034-08-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
